[Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease].

医学 透明质酸钠 他克莫司 眼压 眼科 移植物抗宿主病 视力 外科 移植
作者
S W Liu,Yang Zhao,Jiao Ma,Zhan Shen,Bohao Hu,Rongmei Peng,Jing Hong
出处
期刊:PubMed 卷期号:59 (10): 805-813 被引量:3
标识
DOI:10.3760/cma.j.cn112142-20221112-00585
摘要

Objective: To evaluate the effectiveness and safety of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in treating severe dry eye associated with chronic graft-versus-host disease (cGVHD). Methods: This non-randomized concurrent control trial enrolled 83 eyes from 83 patients with cGVHD-associated severe dry eye. The treatment had two phases. During the initial shock treatment period (0-3 months), 44 patients received 0.05% cyclosporine A eye drops (4 times/day; group A) and 39 patients received 0.1% tacrolimus eye drops (twice/day; group B) alongside basic treatment. In the maintenance treatment period (3-6 months), both groups used 0.05% cyclosporine A eye drops (twice/day) and sodium hyaluronate. Examinations were conducted at 1, 3, and 6 months after treatment initiation, assessing the Ocular Surface Disease Index (OSDI), corneal fluorescein staining (CFS) score, and fluorescein tear break-up time (BUT) for efficacy. visual acuity and intraocular pressure (IOP) were evaluated for safety, and patients' post-medication irritation symptoms were recorded. Results: The study included 52 males and 31 females, aged (28.57±15.67) years. After 1 month of treatment, the CFS score in group A significantly decreased from 10.0 (6.0, 14.0) to 5.0 (3.0, 8.5) (P<0.001). in group B, the CFS score also significantly decreased from 10.0 (6.0, 15.0) to 6.0 (2.0, 10.0), and the BUT increased from 2.0 (1.0, 2.0) s to 2.0 (1.8, 3.3) s (P<0.001). No significant OSDI decrease was observed in either group. No significant differences were found in OSDI, CFS score, and BUT between the two groups. After 3 months, group A showed significant improvement in OSDI, CFS score, and BUT (P<0.05), while group B only demonstrated significant CFS score decrease (P<0.05). OSDI was significantly lower in group A than group B (P<0.05). No significant differences were noted in CFS score and BUT between groups. After 6 months, OSDI, CFS score, and BUT were 18.9 (9.3, 34.2), 7.0 (3.0, 8.5), and 2.0 (1.0, 3.0) s in group A, and 10.9 (3.6, 35.4), 5.5 (2.8, 10.0), and 2.0 (1.0, 10.0) s in group B. In both groups, CFS scores significantly decreased and BUT increased (P<0.05). Visual acuity improved significantly in group A at 1, 3, and 6 months (P<0.05), while no significant changes were seen in group B. Irritation symptoms were transient and self-resolving in both groups. Conclusions: Both 0.05% cyclosporine A and 0.1% tacrolimus eye drops, when combined with local glucocorticoids, exhibited significant anti-inflammatory effects, effectively and safely treating severe dry eye in cGVHD patients. Although the onset of 0.05% cyclosporine A was slower than 0.1% tacrolimus, it offered more stable long-term effects and better symptom improvement.目的: 评估0.05%环孢素A及0.1%他克莫司滴眼液治疗眼部慢性移植物抗宿主病(cGVHD)相关重度干眼的有效性和安全性。 方法: 前瞻性非随机同期对照试验。连续纳入2020年4至2021年6月于北京大学第三医院眼科门诊被诊断为cGVHD相关重度干眼的患者,纳入单眼进行研究。将纳入的患者分为A、B两组:前3个月A组局部给予0.05%环孢素A+0.1%氟米龙+玻璃酸钠+小牛血去蛋白提取物,B组在此基础上增加0.1%他克莫司;后3个月两组均只使用0.05%环孢素A和玻璃酸钠。观察两组患者治疗前和治疗后1、3、6个月的眼表疾病指数(OSDI)评分、角膜荧光素染色(CFS)评分和泪膜破裂时间(BUT),以及视力和眼压,并统计患者用药后的刺激症状。 结果: 共纳入83例(83只眼)眼部cGVHD患者,其中男性52例,女性31例,年龄为(28.57±15.67)岁;其中A组44例,B组39例。治疗后1个月,A组CFS由10.0(6.0,14.0)分降低至5.0(3.0,8.5)分(P<0.001);B组CFS由10.0(6.0,15.0)分降低至6.0(2.0,10.0)分(P<0.001),BUT由2.0(1.0,2.0)s增加至2.0(1.8,3.3)s(P<0.001);两组OSDI均无明显降低(均P>0.05),两组间OSDI、CFS、BUT的差异亦均无统计学意义(均P>0.05)。治疗3个月时,A组OSDI由治疗前的32.5(10.7,51.1)分降低至15.9(7.5,33.7)分(P<0.05),CFS降低至6.0(2.0,9.5)分(P<0.05),BUT增加至2.0 s(1.0,3.5)(P<0.05);B组CFS降低至5.0(3.0,12.0)分(P<0.05),BUT增加至2.0(2.0,3.0)s(P<0.05),OSDI无明显降低(P>0.05);A组OSDI低于B组(P<0.05);两组间CFS、BUT比较差异无统计学意义(均P>0.05)。治疗6个月,A组OSDI评分、CFS评分和BUT分别为18.9(9.3,34.2)分、7.0(3.0,8.5)分和2.0(1.0,3.0)s,B组分别为10.9(3.6,35.4)分、5.5(2.8,10.0)和2.0(1.0,2.0)s。与治疗前相比,A组CFS降低、BUT增加,B组OSDI降低,差异均有统计学意义(P<0.05);CFS、BUT较治疗前无明显改善。安全性:治疗1个月时B组眼压由13.2(11.0,19.0)mmHg(1 mmHg=0.133 kPa)升高至14.8(12.8,18.8)mmHg(P<0.05),但治疗期间两组眼压波动均在正常范围;治疗后A组视力有明显改善(P<0.05),B组视力较治疗前的差异无统计学意义(P>0.05)。用药后刺激症状:A组50%的患者报告使用0.05%环孢素A滴眼液后出现刺激症状,B组80%的患者报告使用0.1%他克莫司滴眼液后出现刺激症状,症状在用药后缓解。 结论: 0.05%环孢素A滴眼液或0.1%他克莫司滴眼液与局部糖皮质激素联用,均能发挥较好的抗炎效果,是治疗眼部cGVHD相关重度干眼安全、有效的手段。0.1%他克莫司滴眼液起效较快;0.05%环孢素A的远期效果更为稳定,改善症状较为明显。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雪白的紫翠完成签到 ,获得积分10
1秒前
哈哈完成签到,获得积分10
2秒前
淡定访琴完成签到,获得积分10
4秒前
大力云朵完成签到,获得积分10
6秒前
ADcal完成签到 ,获得积分10
6秒前
6秒前
tony完成签到,获得积分10
6秒前
苏苏完成签到,获得积分10
8秒前
WuFen完成签到 ,获得积分10
9秒前
淘宝叮咚完成签到,获得积分10
9秒前
高高从云完成签到 ,获得积分10
10秒前
情怀应助唐唐采纳,获得10
11秒前
科研肥料完成签到,获得积分10
12秒前
每天都在找完成签到,获得积分10
12秒前
桐桐应助zzw采纳,获得20
12秒前
12秒前
吕布完成签到,获得积分10
13秒前
13秒前
ChenYifei完成签到,获得积分10
17秒前
qq发布了新的文献求助10
17秒前
Smiley完成签到 ,获得积分10
20秒前
hzauhzau完成签到 ,获得积分10
20秒前
白桃完成签到 ,获得积分10
22秒前
小八统治世界完成签到 ,获得积分10
23秒前
Lotus完成签到,获得积分10
23秒前
btyyl完成签到,获得积分10
24秒前
屈岂愈发布了新的文献求助10
25秒前
26秒前
HH发布了新的文献求助10
27秒前
葵葵完成签到,获得积分10
28秒前
高大莺完成签到 ,获得积分10
30秒前
zzw发布了新的文献求助20
31秒前
幸福果汁完成签到,获得积分10
32秒前
量子星尘发布了新的文献求助10
32秒前
谢谢谢谢谢谢谢谢完成签到 ,获得积分10
33秒前
Akim应助biofresh采纳,获得30
33秒前
长安发布了新的文献求助10
34秒前
35秒前
zzw完成签到,获得积分10
40秒前
Guochunbao完成签到,获得积分10
41秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022